Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition
Navidea Biopharmaceuticals (NYSE American: NAVB) announced a conference call for
- Leadership changes may provide fresh perspectives and direction.
- The conference call indicates a proactive approach in engaging with shareholders.
- Resignation of board members may raise concerns about continuity and experience.
- The company faces ongoing risks, including a history of operating losses and regulatory challenges.
Conference Call to be held
The Company will hold the conference call and webcast on
To participate in the call and webcast, please refer to the information below:
Event: Navidea Biopharmaceuticals Business Update
Date:
Time:
International Dial-In: +1 201-389-0899
Conference ID: 13725627
Webcast Link: https://webcast-eqs.com/navidbioph20211216/en
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
About Navidea
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other
Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005986/en/
Investor Relations Contact
Vice President of Operations
614-822-2365
jsmith@navidea.com
Source:
FAQ
What are the updates from Navidea on December 16, 2021?
Who resigned from the Navidea Board of Directors?
What is the focus of Navidea Biopharmaceuticals?
How can I access the December 16 conference call for Navidea Biopharmaceuticals?